Investor News no. 2/2007
To OMX Nordic Exchange Copenhagen Copenhagen, November 5, 2007
Investor News: Curalogic will present at the Acumen BioFin Rodman & Renshaw
Conference in New York
Curalogic A/S (OMX: CUR) will attend at Acumen BioFin Rodman & Renshaw 9th
Annual Healthcare Conference November 5-7, 2007 in New York.
The presentation will be held by Peter Moldt, Ph.D., President and Chief
Executive Officer of Curalogic and is scheduled for:
Monday 3:45PM local time on November 5, 2007.
The PowerPoint presentation and a audio and archived webcast will be available
at www.curalogic.com.
Yours sincerely
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO Tel +45 99 99 24 00, mobile +45 2625 0422
Helle Busck Fensvig, EVP and CFO Tel +45 99 99 24 00, mobile +45 2070 5537
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic
Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the
treatment of allergy. By combining the best of two worlds - the efficacy of
immunotherapy combined with the safety and patient convenience of symptomatic
treatments - Curalogic aims to develop a novel and user-friendly form of allergy
treatment, and make it the preferred type of allergy treatment among patients.
Curalogic has a broad and mature pipeline with a product for treatment of
ragweed allergy in Phase III, a product for treatment of grass allergy ready for
Phase III, a product for treatment of cat allergy in Phase II and a product for
treatment of house dust mite allergy preparing for clinical trials.
Investor News: Curalogic will present at the Acumen BioFin Rodman & Renshaw Conference in New York
| Source: Curalogic A/S
Attachments
